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ABSTRACT
Increased level of choline kinase (CK) is a common feature in cancers and inhibition of this enzyme has been applied as 
anticancer strategy. DNA methylation of gene promoter especially at CpG island is associated with suppression of gene 
expression. Despite the importance of CK especially the alpha isoform in cancer pathogenesis, epigenetic regulation of 
ckα expression has not been investigated. Hence, this study aimed to determine the effect of DNA methylation on ckα 
promoter activity and gene expression by using hypomethylating (5-aza) and methylating (budesonide) agents. The level 
of DNA methylation in the second CpG island of ckα promoter was determined by PCR-based method. 5-aza and 
budesonide increased the methylation of the selected CpG island compared to untreated control. Treatment with the 
drugs produced opposite effect, with 5-aza induced ckα promoter activity and gene expression while budesonide 
suppressed the promoter activity and mRNA level of this gene. Deletion of a region containing the second CpG island on 
ckα promoter resulted in significantly lower promoter activity. In conclusion, this study showed that DNA methylation 
could be one of the mechanisms that regulate the expression of ckα gene.
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ABSTRAK
Peningkatan tahap kolina kinase (CK) adalah ciri umum kanser dan perencatan enzim ini telah diguna sebagai strategi 
antikanser. Metilasi DNA promoter gen terutamanya pada pulau CpG telah dikaitkan dengan perencatan pengekspresan 
gen. Walaupun CK, terutamanya isoforma alfa, penting dalam patogenesis kanser, pengawalaturan epigenetik 
pengekspresan ckα masih belum pernah dikaji. Maka, kajian ini bertujuan menentukan kesan metilasi DNA terhadap 
aktiviti promoter dan pengekspresan gen ckα dengan menggunakan agen hipometilasi (5-aza) dan metilasi (budesonida). 
Tahap metilasi DNA pada pulau CpG kedua pada promoter ckα telah ditentukan dengan kaedah berdasarkan PCR. 5-aza 
dan budesonida meningkatkan tahap metilasi pulau CpG yang dikaji berbanding kawalan tanpa rawatan. Rawatan 
dengan agen ini menghasilkan kesan berlawanan dengan 5-aza merangsang aktiviti promoter dan pengekspresan gen 
ckα manakala budesonida merencat aktiviti promoter dan tahap mRNA gen ini. Pemadaman salah satu kawasan yang 
mengandungi pulau CpG kedua pada promoter ckα menyebabkan penurunan secara signifikan aktiviti promoter. 
Kesimpulannya, kajian ini menunjukkan metilasi DNA mungkin merupakan salah satu mekanisme yang mengawalatur 
pengekspresan gen ckα.
Kata kunci: Epigenetik; kolina kinase; metilasi DNA; pengekspresan gen
Introduction
Epigenetics were described as heritable changes in gene 
activity without any changes in DNA sequence (Bird 2007). 
Study showed that abnormal epigenetic changes could 
cause developmental abnormalities and diseases (Hon et 
al. 2012). DNA methylation and histone modification are 
two main types of epigenetic modifications. In mammalian 
genome, the most common epigenetic events are DNA 
methylation activities. DNA methyltransferases (DNMTs) 
catalyse this reaction by adding a methyl group to the DNA. 
This reaction takes place at the 5-position (C5) of cytosine 
nucleotides located next to a guanine nucleotide in the DNA 
sequence yielding 5-methyl-cytosine (Bird 1986). 
Increased methylation in the promoter region of a gene 
usually reduces its expression, however, when the 
methylation occurs in the transcribed region, it can produce 
variable effects on gene expression (Singal et al. 2002). 
There are two general ways DNA methylation affect gene 
expression. First is by direct interference on the binding 
of specific transcription factors to their recognition sites 
in gene promoters. For example, E2F, AP-2 and NFkB 
transcription factors recognize the sequences where the 
CpG residues are situated. DNA methylation has been 
shown to inhibit the binding of these transcription factors 
to their target promoters (Comb & Goodman 1990; Watt 
& Molloy 1988). The second mode of repression is by 
direct binding of specific transcriptional repressors 
containing methyl CpG binding domain (MBD) to the 
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methylated DNA (Nan et al. 1998; Prokhortchouk & 
Hendrich 2002). Many important cellular activities such 
as cancer development, cloning and transgenic technologies, 
viral infections, genomic imprinting, X-inactivation and 
development abnormalities, have the footprints of 
epigenetics (Das & Singal 2004). Currently, DNA 
methylation in promoter regions of tumour suppressor 
genes related to oncogenesis is the most extensively 
studied.
Choline kinase (CK) is the first enzyme in the CDP-
choline pathway for biosynthesis of phosphatidylcholine, 
a major phospholipid in the membrane of eukaryotic cells 
(Lykidis et al. 2001). This enzyme catalyzes the ATP 
phosphorylation of choline. There are two choline kinase 
genes in human, ckα and ckβ. Ckα undergoes alternative 
splicing to produce CKα1 and CKα2 isozymes while ckβ 
codes for a single protein (CKβ) (Malito et al. 2006). 
Increased CK activity has been associated with 
carcinogenesis (Lacal 2015). Overexpression of CKα in 
several human tumor-derived cell lines including lung, 
colon and prostate carcinomas has been detected (Gallego-
Ortega et al. 2011; Ramirez de Molina et al. 2002; Shah et 
al. 2010). Breast cancer resistance to drug and increased 
invasiveness have also been linked to CK overexpression 
(Shah et al. 2010). CK affects genes involve in cell 
proliferation, transformation, apoptosis and cell cycle 
(Ramirez de Molina et al. 2008). Rodriguez-Gonzalez et 
al. (2004) demonstrated the potential of CKα inhibitors as 
antitumor drugs in vitro and in vivo. Therefore, CK could 
become diagnostic indicator of cancer and marker for 
monitoring tumor response to therapies (Wu & Vance 
2010). Gruber et al. (2012) also mentioned that the balance 
of CK α and β isoforms was crucial for cell cycle regulation. 
Interestingly, the regulation of CK gene expression by 
epigenetic mechanism, particularly DNA methylation has 
never been explored.
Many researches have focused on the abnormal 
expression of CKα in different cancer cells and the potential 
of CKα inhibition as anticancer therapy. Various compounds 
for CKα inhibition have been synthesized and tested 
(Gomez-Peres et al. 2012). Yet, not much attention has 
been given to the intracellular regulation of CK gene 
expression, including by epigenetic mechanism.
We previously observed increased ckα expression in 
cells treated with trichostatin A (TSA), a drug that could 
indirectly cause DNA demethylation. Thus, this study 
aimed to investigate the effect of DNA methylation on ckα 
gene promoter activity and expression by utilizing 5-aza 
as demethylating agent and budesonide as methylating 
agent. The effect of these drugs on the level of DNA 
methylation at a selected CpG island on ckα promoter was 
also investigated. The results suggest the involvement of 
DNA methylation in ckα gene expression and the possible 
use of epigenetic drugs to suppress choline kinase activity 
in cancer cells.
Materials and Methods
prediction of cpg island
CpG plot was used to determine the location of CpG islands 
at the ckα and ckβ promoters. This software is freely 
available at the European Molecular Biology Open 
Software Suite (EMBOSS) (http://www.ebi.ac.uk/emboss/
cpgplot). CpG island is defined as a region with more than 
50% GC content and observed/expected ratio > 0.6, 
covering at least 200 bp.
mammalian cell culture
HeLa cell line (ATCC no. CCL-2) was originally purchased 
from American Type Culture Collection (Manassas, VA, 
USA) and maintained at 37°C with 5% CO2 in Dulbecco’s 
Modified Eagle Medium (DMEM) (Thermo Fisher 
Scientific, Waltham, MA, USA) containing 10% (v/v) fetal 
bovine serum (Thermo Fisher Scientific, Waltham, MA, 
USA), 100 µg/mL penicillin and streptomycin (Thermo 
Fisher Scientific, Waltham, MA, USA). Cells were passaged 
at pre-confluent densities every 2 to 3 days to a maximum 
passage number of 20. HeLa cells were used in this study 
because it has been shown to express ckα gene (Gruber et 
al. 2012).
treatment of cells with epigenetic drugs: 5-aza 
(demethylating agent) and budesonide 
(methylating agent)
To manipulate the levels of DNA methylation, cells were 
treated with either DNA methylation inhibitor, 5’-aza 
(Sigma-Aldrich, St. Louis, MO, USA) or DNA methylating 
agent, budesonide (Sigma-Aldrich, St. Louis, MO, USA), 
at 7.5 μM for 5-aza and 70 µM for budesonide, for 12-24 
h. DMSO (Sigma-Aldrich, St. Louis, MO, USA) was used 
to replace the epigenetic drugs in the negative control 
samples.
qualitative estimation of dna methylation level
DNA methylation at specific ckα promoter region was 
estimated by Methylation Sensitive Dimethyl Sulfoxide 
PCR (MS-DMSO-PCR) as described by Kholod et al. (2007). 
The reaction mixture (25 µL) contained 1.5 units KOD Hot 
Start DNA polymerase (Sigma-Aldrich, St. Louis, MO, 
USA), 1 × KOD Hot Start DNA polymerase buffer, 0.4 µM 
of each primers (as stated), 0.2 mM of each dNTP, 1.5 mM 
MgCl2, 0-8% DMSO, and 25 ng genomic DNA template. 
PCR was run with the following protocol: Initial 
denaturation at 95°C for 3 min; followed with 30 cycles 
of denaturation at 95°C for 45 s, annealing at 56°C for 30 
s, and extension at 72°C for 1 min. The final extension was 
at 72°C for 5 min. The PCR primers used for ckα promoter 
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region with expected amplicon size of 216 bp were 
5’-GACAGGGAAACTGAGGCTGC-3’ (forward) and 
5’-GCTCAGTGGGTGTGATTTTG-3’ (reverse). The positive 
control used was β-actin and the primer sequences were 
5’-CTGGGACGACATGGAGAAAA-3’ (forward) and 
5’-AAGGAAGGCTGGAAGAGTGC-3’ (reverse). The PCR 
products were analyzed with 1.5% agarose gel.
pcr site directed mutagenesis of choline kinase 
promoter
Three deletion constructs of ckα promoter were made by 
PCR site directed mutagenesis according to Ho et al. (1989). 
The PCR protocol was as described above with full length 
ckα plasmid construct as template and no DMSO was added 
into the reaction. The mutated promoters were cloned into 
pCR2.1-TOPO vector (Thermo Fisher Scientific, Waltham, 
MA, USA) and confirmed by sequencing before subcloning 
into the firefly luciferase reporter vector, pGL4.10(luc2) 
(Promega, Madison, WI, USA).
transfection and quantitation of promoter 
activity by dual-glo luciferase assay
Full length (2000 bp) and mutant ckα promoter constructs 
were transiently transfected into HeLa cells to investigate 
the importance of the deleted regions for promoter 
activities. Twenty-four hours prior to transfection, 0.5 - 2.0 
× 105 cells were seeded into each well of a 24-well dish 
containing 500 µL of DMEM growth medium without 
antibiotics. The co-transfection of cells with firefly 
luciferase ckα promoter constructs and Renilla luciferase 
vector was done using Lipofectamine 3000 (Thermo Fisher 
Scientific, Waltham, MA, USA) transfection reagent. 
Briefly, 80 ng of pGL4.10(luc2) firefly luciferase constructs 
and 40 ng of pGL4.73(hRluc/SV40) Renilla luciferase 
vector (Promega, Madison, WI, USA) were diluted in 50 
mL of Opti-MEM I medium (Thermo Fisher Scientific, 
Waltham, MA, USA) without serum. In another tube, 1 µL 
of Lipofectamine 3000 was also diluted in 50 mL of Opti-
MEM I medium. After 5 min, the contents from both tubes 
were mixed and incubated at room temperature for 20 min. 
FIGURE 1. MS-DMSO-PCR of ckα CpG island after treatment with 5-aza. PCR amplifications were performed in reactions 
containing the indicated DMSO concentrations with genomic DNA purified from either DMSO treated (negative control) or 5-aza 
(7.5 µM) treated HeLa cells. M: Size marker; +: Positive control (β-actin)
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Transfection was done by adding 100 mL of the mixture 
into each well containing cells and medium as described 
above followed by incubation at 37oC with 5% CO2 for 48 h.
Both firefly and control Renilla luciferase activities of 
the transfected cells were assayed with Dual-Glo Luciferase 
assay system (Promega, Madison, WI, USA) according to 
the manufacturer’s instructions. Promoterless pGL4.10(luc2) 
vector was the experimental negative control, whereas the 
pGL4.73(hRluc/SV40) Renilla luciferase vector which was 
regulated by SV40 promoter was the control vector for 
signal normalization of each transfection assay. Promoter 
activity was expressed as relative firefly luciferase activity 
normalized to Renilla luciferase activity. The luciferase 
activities were measured with GloMax 20/20 luminometer 
(Promega, Madison, WI, USA).
quantification of ckα gene expression by real-time 
pcr
RNeasy total RNA extraction kit (Qiagen, Hilden, 
Germany) was used to extract the total RNA from 1 × 106 
cells. The total RNA was converted to cDNA with 
RevertAid H Minus First Strand cDNA synthesis kit 
(Thermo Fisher Scientific, Waltham, MA, USA) according 
to the manufacturer’s protocol. Quantitative real-time 
PCR (qPCR) by relative method was performed using the 
ABI PRISM 7000 Sequence Detection System (Thermo 
Fisher Scientific, Waltham, MA, USA). Each reaction 
consisted of 25 µL total volume containing 12.5 µL Power 
SYBR Green I Master Mix (Thermo Fisher Scientific, 
Waltham, MA, USA), 300 nM each ckα specific primers 
(forward primer: 5’-TCAGAGCAAACATCCGGAAGT-3’, 
reverse primer: 5’-GGCGTAGTCCATGTACCCAAAT-3’, 
size of PCR product: 239 bp) or 1 µL each of reference 
gene primers and 1 µL of 1:2 diluted cDNA. Primers for 
the two reference genes (UBC and YWHAZ, primer 
sequences were not disclosed by the company) used in 
this study were purchased from TATAA Biocenter, 
Goteborg, Sweden. The settings for thermal cycling were 
2 min at 50°C, 10 min at 95°C, followed by 40 cycles of 
10 s at 95°C and 1 min at 60°C. Melting curve analysis 
was carried out at the end of a run with temperatures 
FIGURE 2. MS-DMSO-PCR of ckα CpG island after treatment with budesonide. PCR amplifications were performed in reactions 
containing the indicated DMSO concentrations with genomic DNA purified from either DMSO treated (untreated) or budesonide 
treated HeLa cells. M: Size marker; +: Positive control (β-actin)
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ranging from 60 to 95°C in 0.1°C increments to verify 
the PCR specificity.
statistical analysis
All data were analyzed using Student’s t-test and one-way 
analysis of variance (ANOVA) with the Bonferroni post hoc 
test. P<0.05 was considered to indicate a statistically 
significant difference, and all analyses were performed 
using SPSS software version 22.0 (IBM Corp., Armonk, 
NY, USA). All data are presented as the mean ± standard 
deviation from at least triplicates of two independent 
experiments.
Results
effect of budesonide and 5-aza on the methylation 
level at second cpg island, promoter activity and 
expression of ckα gene
Prediction with CpG Plot program showed that ckα promoter 
contained four putative CpG islands within 2000 bp 
upstream from the ATG start codon. The four CpG islands 
were predicted to be located at regions between -57 and 
-566, -696 and -908, -1383 and -1513, and -1595 and -1722 
(+1 denotes the first nucleotide of the ATG start codon).
MS-DMSO-PCR method was used to probe the effect 
of 5-aza and budesonide treatments on the methylation 
level of the second CpG island on ckα promoter (-908 to 
-696). The principle of this method is based on higher 
percentage of DMSO is required for PCR amplification 
when the level of methylation is higher. The second CpG 
island was selected for this experiment because deletion 
of promoter region covering this CpG island produced 
significant effect on promoter activity and a CEBP-alpha 
transcription factor binding site was predicted to be located 
in this CpG island by MatInspector 8.0 and TFSearch 
programs. Despite 5-aza being known as a demethylating 
agent, results in Figure 1 show that treatment with this drug 
increased the level of DNA methylation as the visible PCR 
product appeared at higher DMSO concentration (2%, lower 
panel) compared to 1% DMSO (upper panel) for PCR of 
genomic DNA purified from negative control cells. Figure 
2 shows that budesonide treatment resulted in higher level 
of DNA methylation as expected with visible PCR product 
appeared at 2% DMSO (lower panel) compared to 1% 
DMSO (upper panel) for negative control.
Treatment with 5-aza significantly increased ckα 
promoter activity by about 2.5 fold (p<0.01) while 
budesonide treatment significantly decreased the promoter 
activity by about 0.7 fold (p<0.05) compared to control 
(Figure 3, left panel). 5-aza and budesonide treatment also 
showed similar effect on ckα gene expression. Treatment of 
5-aza significantly increased the level of ckα mRNA by 2.8 
(p<0.01). Conversely, budesonide treatment significantly 
decreased the mRNA level of ckα by 1.4 fold compared to 
negative control (p<0.05) (Figure 3, right panel).
identification of ckα promoter regulatory regions
As shown in Figure 4, deletion of the region from -818 to 
-1790 significantly increased the ckα promoter activity 
(p<0.001). The deleted region covers part of the second 
CpG island and the whole of third and fourth CpG islands 
on ckα promoter. Interestingly, deletion of the region from 
-546 to -818 (mainly located in the second CpG island) of 
ckα promoter resulted in significant decrease of promoter 
activity (p<0.001). The results indicate the presence of 
important positive regulatory elements at the second CpG 
island, which could be modulated by DNA methylation.
Discussion
CpG islands are mostly found at the 5’-end of housekeeping 
genes, at their promoters and transcription start sites. They 
are considered as gene markers because of their important 
FIGURE 3. Effect of 5-aza and budesonide treatment on ckα promoter activity and gene expression. All data were reported as means 
± SD. Statistical analysis was performed using independent t-test. **p<0.01 or *p<0.05 vs negative control treated with DMSO
**
**
* *
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role in gene regulation via epigenetic mechanism including 
DNA methylation (Du et al. 2012). DNA methylation is 
said to be the mechanism that represses the activity of gene 
promoters containing CpG islands (Deaton & Bird 2011). 
CpG methylation causes transcription repression by direct 
blockage of transcription initiation complexes and 
recruitment of co-repressor complexes to create repressive 
chromatin environment (Sasai et al. 2010). Computational 
prediction showed four CpG islands in the ckα promoter, 
which suggests that DNA methylation could play significant 
role in the regulation of ckα gene expression. The 
importance of the second CpG island in ckα promoter was 
supported by the significant change in promoter activity 
after mutagenesis of region encompassing this CpG island.
In this study, two epigenetic drugs (5-aza and 
budesonide) have been tested to manipulate the levels of 
DNA methylation in the second CpG island of ckα 
promoter. 5-aza is an analog of cytidine that acts as 
hypomethylating agent. It is incorporated into cellular DNA 
with subsequent sequestration of DNA methyltransferases 
(Christman 2002). Budesonide is classified as DNA 
methylating agent and it has the ability to inhibit cell 
proliferation dependent on cell type (Liang et al. 2014). 
However, this study shows that 5-aza increased the level 
of DNA methylation in the second CpG island of ckα 
promoter. Previously, 5-aza also increased the expression 
of somatostatin (SST) gene and SST receptor 2, 4 and 5 in 
pancreatic ductal adenocarcinoma cell line (Gailhouste et 
al. 2018). Budesonide treatment produced the expected 
results where it increased the levels of DNA methylation 
in the second CpG island of ckα promoter. The results point 
to the potential use of budesonide to manipulate the level 
of DNA methylation in ckα gene promoter. However, it 
must be noted that the effect could be cell type dependent.
There are different methods to study the level of DNA 
methylation, in this study we have chosen the MS-DMSO-
PCR method to qualitatively compare the levels of DNA 
methylation at the selected CpG island before and after 
treatment with epigenetic drugs. This method is more 
simple, efficient and cost effective than bisulfite sequencing 
method. Real-time PCR instead of conventional PCR could 
be used for quantitative determination of DNA methylation 
level with this method. Ideally, the levels of DNA 
methylation after treatments with 5-aza and budesonide 
are also verified by other PCR-based methods applying 
different principles such as enrichment of 5-methylcytosine 
with antibodies or digestion-based assay with methylation-
sensitive restriction endonucleases (Kurdyukov & Bullock 
2016).
DNA methylation is usually associated with the 
suppression of gene expression. This is in line with our 
observations where budesonide decreased the promoter 
activity and gene expression of ckα, possibly due to the 
hypermethylation induced by budesonide. Budesonide is 
designated as DNA methyltransferase activator (Ciechomska 
et al. 2019), which was used to modulate the level of DNA 
FIGURE 4. Effect of deletion mutagenesis on ckα promoter activity. Promoter constructs (200 ng) were co-transfected with Renilla 
luciferase internal control vector (2.5 ng) into the cells. Luciferase activities were measured by luminometer 48 h after transfection. 
All data were reported as means ± SD. Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test.  
*p<0.001
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methylation in mouse lung tumors and alter the expressions 
of several cancer-related genes (Pereira et al. 2006). 
Budesonide has also been shown to decrease the size of 
non-solid nodules that may progress to adenocarcinoma 
of the lung (Veronesi et al. 2015). In terms of clinical 
significance, this study indicates the possible use of 
budesonide to downregulate the expression of ckα for 
anticancer therapy. More effective treatment could also be 
achieved by the combination of budesonide and choline 
kinase inhibitors, similar to the more effective prevention 
of mouse lung tumors with the combination of budesonide 
and R115777 (a farnesyl transferase inhibitor) (Alyaqoub 
et al. 2007).
Conclusion
This study showed the effect of epigenetic drugs on the 
methylation status of a selected CpG island in ckα promoter. 
The effect of these drugs on ckα promoter activity and 
expression supports the possible role of DNA methylation 
in regulating ckα gene function. A few limitations of this 
study that must be addressed in the future which include 
the use of only one cell line as well as only one 5-aza and 
budesonide concentrations. Yet, this work provides the first 
indication of a possible regulation of ckα gene by DNA 
methylation and the potential use of budesonide to 
modulate ckα expression for cancer therapy. In future, more 
studies are required to look at the direct effect of DNA 
methylation on the binding of transcription factors onto 
the CpG islands of ckα promoter. Mutagenesis of specific 
transcription factor binding sites could also be performed 
to obtain a better understanding of how DNA methylation 
regulates the expression of ckα gene.
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